Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1.3% (low dose) | Active Comparator |
| |
| 2% (medium dose) | Active Comparator |
| |
| 2.6% (high dose) | Active Comparator |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LiquiTears | Drug | 4 drops applied daily for 360 days |
| |
| C-KAD Ophthalmic Solution |
| Measure | Description | Time Frame |
|---|---|---|
| Best-corrected visual acuity by ETDRS | 360 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sanduk Ruit, MD | Tilganga Eye Center | Principal Investigator |
| Reeta Gurung, MD | Tilganga Eye Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tilganga Eye Center | Kathmandu | Kathmandu | Nepal |
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
4 drops applied daily for 360 days |
|
| C-KAD Ophthalmic Solution | Drug | 4 drops applied daily for 360 days |
|
| C-KAD Ophthalmic Solution | Drug | 4 drops applied daily for 360 days |
|